# 2025年11月8日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 伴与不伴急性脑损伤患者的机械通气策略：一项基于注册的队列研究。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41201309](https://pubmed.ncbi.nlm.nih.gov/41201309)
**期刊：** Critical care medicine
**PMID：** 41201309
**DOI：** 10.1097/CCM.0000000000006931

### 第一部分 原文与翻译

**英文原标题：** Approaches to Mechanical Ventilation in Patients With and Without Acute Brain Injury: A Registry-Based Cohort Study.

**英文摘要原文：**
OBJECTIVES: Differences in mechanical ventilation strategies between patients with and without acute brain injury (ABI) remain incompletely characterized. We aimed to compare ventilation approaches in patients with and without ABI over a 10-year period and to investigate impacts of practice changes on Pao2 and Paco2.

DESIGN: Retrospective registry-based cohort study involving prospectively collected data from nine ICUs across Toronto, Ontario, Canada.

SETTING AND PATIENTS: Adult patients (≥ 18 yr) receiving invasive ventilation for at least 48 hours from 2014 to 2023 were included. Patients were classified as having ABI (exposure) or non-ABI (comparator) conditions. Between-group differences in tidal volume (Vt), positive end-expiratory pressure (PEEP), Paco2, and Pao2 were summarized using adjusted linear mixed-effects regression. Six additional ventilation and gas exchange variables were evaluated in unadjusted analyses.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Thirteen thousand nine hundred twenty-five patients were included. Mean age (sd) was 59.1 years (17.5 yr), 38.1% of patients (n = 5305) were female, and 25.2% had ABI (n = 3503). Over the first 7 ventilation days, Vt was comparable between groups, with a daily median close to 6 mL/kg (interquartile range, 6-7 mL/kg) predicted body weight. PEEP was significantly lower in patients with ABI (median 5 vs. 8 cm H2O in non-ABI patients; p < 0.001). Among patients with hypoxemic respiratory failure, PEEP remained significantly lower in the ABI subset. From 2014 to 2023, Vt decreased slightly in both groups, while PEEP remained unchanged. Paco2 was largely maintained within 35-45 mm Hg in ABI patients and Pao2 remained largely within 80-120 mm Hg. Differences in six additional ventilation parameters between groups were minimal.

CONCLUSIONS: Both ABI and non-ABI patients received comparable Vt that trended downwards over time. Paco2 and Pao2 remained largely within guideline-recommended ranges. However, PEEP was significantly lower in ABI patients, including among those with hypoxemic respiratory failure, highlighting potential opportunities to improve PEEP application in relevant subsets.

**中文摘要译文：**
目的：伴与不伴急性脑损伤（ABI）患者在机械通气策略上的差异尚未被完全阐明。我们旨在比较伴与不伴ABI患者在十年间的通气方法，并研究临床实践变化对动脉血氧分压（Pao2）和动脉血二氧化碳分压（Paco2）的影响。

设计：一项基于注册的回顾性队列研究，数据来源于加拿大多伦多市九家ICU前瞻性收集的数据。

地点与患者：纳入2014年至2023年间接受有创通气至少48小时的成年患者（≥18岁）。患者被分为ABI（暴露组）和非ABI（对照组）。使用调整后的线性混合效应回归模型总结组间在潮气量（Vt）、呼气末正压（PEEP）、Paco2和Pao2方面的差异。在未经调整的分析中，还评估了另外六个通气和气体交换变量。

干预措施：无。

测量与主要结果：共纳入13925名患者。平均年龄为59.1岁（标准差17.5岁），38.1%（n = 5305）为女性，25.2%（n = 3503）患有ABI。在通气的头7天内，两组的潮气量相当，每日中位数接近6 mL/kg预测体重（四分位距为6-7 mL/kg）。ABI患者的PEEP显著更低（中位数为5 cm H2O，非ABI患者为8 cm H2O；p < 0.001）。在伴有低氧性呼吸衰竭的患者中，ABI亚组的PEEP仍然显著更低。从2014年到2023年，两组的潮气量均略有下降，而PEEP保持不变。ABI患者的Paco2基本维持在35-45 mm Hg范围内，Pao2基本维持在80-120 mm Hg范围内。两组间另外六个通气参数的差异极小。

结论：ABI和非ABI患者接受了相当的潮气量，且该值随时间推移呈下降趋势。Paco2和Pao2基本保持在指南推荐范围内。然而，ABI患者的PEEP显著更低，包括那些伴有低氧性呼吸衰竭的患者，这凸显了在相关亚组中改进PEEP应用的潜在机会。

### 第二部分 AI 大师评价

本研究是一项大规模、长达十年的注册队列研究，旨在揭示真实世界中急性脑损伤（ABI）与非ABI患者机械通气策略的差异。其核心发现是，尽管潮气量设置趋于一致并符合肺保护策略，但ABI患者的PEEP水平显著偏低，即使在合并低氧性呼吸衰竭时也是如此。这一发现具有重要的临床警示价值，提示临床医生可能因担心颅内压而对ABI患者应用PEEP过于保守，为优化脑损伤患者的呼吸支持、平衡脑保护与肺保护策略提供了关键证据和改进方向。

---

## 2. 负责任地使用人工智能改善肾脏护理：美国肾脏病学会声明

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41201255](https://pubmed.ncbi.nlm.nih.gov/41201255)
**期刊：** Journal of the American Society of Nephrology : JASN
**PMID：** 41201255
**DOI：** 10.1681/ASN.0000000929

### 第一部分 原文与翻译

**英文原标题：** Responsible Use of Artificial Intelligence to Improve Kidney Care: A Statement from the American Society of Nephrology.

**英文摘要原文：**
Artificial intelligence (AI) is rapidly transforming the delivery of kidney care through predictive analytics, machine learning, deep learning, and generative AI technologies. To meet this challenge, the American Society of Nephrology convened an AI Workgroup to provide a framework for the responsible use of AI in nephrology. The group outlines foundational principles to guide AI development: prioritizing patient benefit, ensuring clinician oversight, and advancing innovation in high-burden disease areas. Its set of foundational assumptions are grounded in the physician always being in the loop and an overarching goal to benefit patients with kidney disease. This review provides an overview of the clinical uses of AI in nephrology and offers practical guidance for nephrologists seeking to incorporate AI into CKD and AKI management, dialysis, and transplantation care. It also highlights key challenges-such as data quality, equity, transparency, and clinical integration-that must be addressed to ensure the responsible and effective implementation of AI in kidney care.

**中文摘要译文：**
通过预测分析、机器学习、深度学习和生成式人工智能技术，人工智能（AI）正在迅速改变肾脏护理的提供方式。为应对这一挑战，美国肾脏病学会召集了一个人工智能工作组，为在肾脏病学领域负责任地使用人工智能提供一个框架。该工作组概述了指导人工智能发展的基本原则：优先考虑患者获益，确保临床医生监督，以及在高负担疾病领域推进创新。其一系列基本假设的基础是医生始终处于决策环路中，以及为肾脏病患者带来益处的总体目标。这篇综述概述了人工智能在肾脏病学领域的临床应用，并为寻求将人工智能融入慢性肾脏病（CKD）和急性肾损伤（AKI）管理、透析及移植护理的肾脏科医生提供了实用指导。文章还强调了数据质量、公平性、透明度和临床整合等关键挑战，必须解决这些挑战才能确保人工智能在肾脏护理中得到负责任且有效的实施。

### 第二部分 AI 大师评价

该文是美国肾脏病学会（ASN）发布的一份重要声明，旨在为人工智能（AI）在肾脏病学领域的负责任应用提供框架性指导。文章系统性地阐述了AI发展的核心原则，即患者优先、临床医生监督和推动创新，并为AI在慢性肾病、急性肾损伤、透析及移植等领域的应用提供了实践指南。此声明的价值不在于提供新的实验数据，而在于为这一新兴技术在临床的整合、开发和监管确立了权威基调，对保障技术应用的伦理、公平和透明具有深远的指导意义。

---

## 3. 长时间俯卧位通气在成年急性呼吸窘迫综合征（ARDS）患者中的有效性与安全性：一项系统综述与荟萃分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41199320](https://pubmed.ncbi.nlm.nih.gov/41199320)
**期刊：** Critical care (London, England)
**PMID：** 41199320
**DOI：** 10.1186/s13054-025-05712-0

### 第一部分 原文与翻译

**英文原标题：** Effectiveness and safety of prolonged prone positioning in adult patients with acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis.

**英文摘要原文：**
BACKGROUND: Prolonged prone positioning (PPP) for ≥ 24 h may enhance outcomes in moderate to severe acute respiratory distress syndrome (ARDS), but may also increase risks such as pressure injuries and complications. Despite clinical rationale, high-quality evidence for PPP's safety and efficacy remains scarce.

METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials (RCT) and observational studies. Trials that compared two distinct treatment groups in adult patients with ARDS were included: prone position < 24 h (standard) and ≥ 24 h (prolonged). Databases searched included MEDLINE, CENTRAL, ClinicalTrials.gov, ISRCTN, ICTRP and the Cochrane Covid-19 Study Register (last search: 3 July 2025). Risk of bias was assessed using ROB-2 for RCTs, and the ROBINS-I V2 tool for non-randomised intervention studies (NRSI). The primary outcome was mortality. Secondary outcomes included improvement of oxygenation and adverse events. Outcomes (Risk ratios and hazard ratios) were calculated using a random-effect model with 95% confidence intervals (CI). The quality of evidence was evaluated using the GRADE assessment.

RESULTS: Of 19,986 records, 9 (n = 1,045) were included in the qualitative and quantitative analysis. Four studies, including two small RCTs (n = 112) and two NRSIs (n = 581), had a low to moderate risk of bias. Most studies included patients with COVID-19 ARDS. Meta-analysis showed no significant effect on 90-day mortality (n = 641, HR 0.72; 95% CI 0.41-1.25). No heterogeneity was detected among studies (I² = 0%), but the confidence interval for I² was wide (95% CI: 0-89%), suggesting the possibility that substantial heterogeneity may exist. Similarly, no significant differences were found for secondary outcomes.

DISCUSSION: Current evidence does not support the use of PPP outside of clinical studies. Pooled data from small trials and NRSIs reveal no significant effect of PPP on mortality, oxygenation, or safety outcomes. The evidence is of low to very low certainty, limited by inconsistency and imprecision. The wide confidence intervals indicate low statistical power, therefore both harm and benefit remain plausible on the basis of the available evidence. Well-powered RCTs are needed to clarify the potential benefits and risks of PPP in ARDS.

**中文摘要译文：**
背景：对于中度至重度急性呼吸窘迫综合征（ARDS）患者，持续时间≥24小时的长时间俯卧位通气（PPP）可能改善预后，但也可能增加压力性损伤和并发症等风险。尽管存在临床理论依据，但关于长时间俯卧位通气安全性和有效性的高质量证据仍然缺乏。

方法：我们对随机对照试验（RCT）和观察性研究进行了一项系统综述与荟萃分析。纳入的研究在成年ARDS患者中比较了两个不同的治疗组：俯卧位通气<24小时（标准组）和≥24小时（长时间组）。检索的数据库包括MEDLINE、CENTRAL、ClinicalTrials.gov、ISRCTN、ICTRP和Cochrane Covid-19研究注册库（最后检索日期：2025年7月3日）。我们使用ROB-2工具评估RCT的偏倚风险，使用ROBINS-I V2工具评估非随机干预研究（NRSI）的偏倚风险。主要结局是死亡率。次要结局包括氧合改善和不良事件。使用随机效应模型计算结局指标（风险比和风险比），并给出95%置信区间（CI）。采用GRADE方法评估证据质量。

结果：在检索到的19,986条记录中，共有9项研究（n=1,045）被纳入定性和定量分析。其中四项研究（包括两项小型RCTs，n=112；两项NRSIs，n=581）具有低至中度偏倚风险。大多数研究纳入的是COVID-19 ARDS患者。荟萃分析显示，长时间俯卧位通气对90天死亡率没有显著影响（n=641, HR 0.72; 95% CI 0.41-1.25）。研究间未检测到异质性（I² = 0%），但I²的置信区间很宽（95% CI: 0-89%），这表明可能存在显著的异质性。同样，在次要结局方面也未发现显著差异。

讨论：现有证据不支持在临床研究之外使用长时间俯卧位通气。来自小型试验和非随机干预研究的汇总数据显示，长时间俯卧位通气对死亡率、氧合或安全性结局均无显著影响。由于不一致性和不精确性，该证据的确定性为低至极低。宽泛的置信区间表明统计功效较低，因此根据现有证据，获益和损害的可能性并存。未来需要开展功效充足的随机对照试验，以阐明长时间俯卧位通气在ARDS患者中的潜在获益与风险。

### 第二部分 AI 大师评价

本研究通过系统综述与荟萃分析，首次聚焦于评估延长俯卧位通气时长（≥24小时）相较于标准时程在ARDS成人患者中的有效性与安全性。研究发现，尽管临床上存在延长俯卧位时间的趋势，但现有证据（主要来自小型研究）并未显示其在降低90天死亡率、改善氧合或安全性方面有显著优势。该研究的价值在于明确了当前证据的局限性（证据等级低、统计功效不足），强调在缺乏更有力证据前不应常规推荐此做法，并为未来开展大规模随机对照试验指明了方向。

---

## 4. 整合策略：将微生物组疗法融入肺炎治疗

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198406](https://pubmed.ncbi.nlm.nih.gov/41198406)
**期刊：** The European respiratory journal
**PMID：** 41198406
**DOI：** 10.1183/13993003.01701-2025

### 第一部分 原文与翻译

**英文原标题：** The ensemble approach: integrating microbiome therapeutics into our treatment of pneumonia.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

根据本文标题推断，这可能是一篇前瞻性的综述或观点性文章，旨在探讨如何将微生物组疗法系统性地整合入现有的肺炎治疗方案中。文章的核心理念“整合策略”（ensemble approach）很可能倡导将多种微生物干预手段与传统抗生素治疗相结合，以恢复肺部微生态平衡并提升治疗效果。该文的价值在于为肺炎治疗提供了一个超越“单一病原体-单一药物”模式的创新框架，强调了调节宿主微生态在感染性疾病管理中的潜力。尽管只是一个概念性提出，但它为未来的临床研究和个体化治疗策略开发指明了新方向。

---

## 5. 与静脉型胸廓出口综合征相关的慢性血栓栓塞性肺动脉高压：一项回顾性病例系列研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198403](https://pubmed.ncbi.nlm.nih.gov/41198403)
**期刊：** The European respiratory journal
**PMID：** 41198403
**DOI：** 10.1183/13993003.01610-2025

### 第一部分 原文与翻译

**英文原标题：** Chronic thromboembolic pulmonary hypertension associated with venous thoracic outlet syndrome: a retrospective case series.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

该研究通过回顾性病例系列分析，旨在探讨静脉型胸廓出口综合征与慢性血栓栓塞性肺动脉高压（CTEPH）之间的潜在关联。这项研究的价值在于揭示了上肢深静脉血栓的特定病因（胸廓出口压迫）可能是CTEPH的一个罕见但重要的危险因素，拓展了对CTEPH病因学的传统认识。尽管作为病例系列研究，其在建立因果关系方面存在局限性，但它为临床医生诊断不明原因CTEPH时提供了新的思路，并为未来的前瞻性研究指明了方向。

---

## 6. 急性呼吸窘迫综合征（ARDS）患者疾病严重程度与机械通气强度的预后价值：一项基于LUNG SAFE队列的分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198396](https://pubmed.ncbi.nlm.nih.gov/41198396)
**期刊：** The European respiratory journal
**PMID：** 41198396
**DOI：** 10.1183/13993003.00742-2025

### 第一部分 原文与翻译

**英文原标题：** Prognostic value of disease severity and mechanical ventilation intensity in Acute Respiratory Distress Syndrome. Analysis of the LUNG SAFE cohort.

**英文摘要原文：**
BACKGROUND: We aimed to assess the prognostic performance of different indexes of oxygenation, respiratory mechanics and ventilation intensity in predicting 90-day mortality, and to estimate their independent associations, in a "real world" observational cohort of acute respiratory distress syndrome (ARDS) patients on ICU mortality.

METHODS: This is a secondary analysis of the "Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure" (LUNG SAFE), an international prospective cohort study of patients with severe respiratory failure involving 459 Intensive Care Units (ICUs) from 50 countries. We evaluated prognostic performance of oxygenation (PaO/FiO), respiratory mechanics (normalized elastance) and ventilation intensity (plateau pressure, driving pressure (DP); 4DP+RR and mechanical power (MP)) measured on day 1 of controlled mechanical ventilation in ARDS patients, with respect to ICU mortality within 90 days of admission. For each parameter, associations with mortality were assessed using logistic regression models, estimating effect sizes (odds ratios, OR with 95% confidence interval, CI), model discrimination (area under the ROC curve), calibration, and overall predictive accuracy.

RESULTS: Among 2813 early ARDS patients, 516 (18.3%) met inclusion criteria: mean age 60 years (±16), 61% male. Normalized elastance, plateau, DP and 4DP+RR were significantly associated with mortality, with adjusted ORs ranging from 1.02 (95%CI 1.01-1.03) for 4DP+RR to 1.48 (95%CI 1.15-1.95) for normalized elastance. These parameters showed higher predictive accuracy for mortality compared to PaO/FiO and MP. MP showed a U-shaped relationship with mortality abut it was not significantly associated with it. Its predictive accuracy decreased after accounting for positive end-expiratory pressure (PEEP) and dynamic resistance, with PEEP also demonstrating a U-shaped association with mortality.

CONCLUSIONS: Normalized elastance, DP and 4DP+RR-measured at day1 of ARDS-were best predictors of ICU mortality, and outperformed oxygenation and MP. DP showed the best balance between predictive accuracy and clinical simplicity. These results reinforce the importance of focusing on DP and 4DP+RR as key metrics to guide lung-protective strategies and ARDS severity classification.

**中文摘要译文：**
背景：本研究旨在评估在一个“真实世界”的急性呼吸窘迫综合征（ARDS）患者观察性队列中，不同氧合、呼吸力学和通气强度指标在预测90天内ICU死亡率方面的预后表现，并评估它们的独立关联性。

方法：本研究是对“了解全球严重急性呼吸衰竭影响的大型观察性研究”（LUNG SAFE）的二次分析，该研究是一项国际性前瞻性队列研究，涵盖了来自50个国家的459个重症监护室（ICU）的严重呼吸衰竭患者。我们评估了ARDS患者在接受控制性机械通气第1天测量的氧合（PaO₂/FiO₂）、呼吸力学（标准化肺弹性）和通气强度（平台压、驱动压（DP）；4×DP+RR以及机械功率（MP））等指标，在预测入院90天内ICU死亡率方面的预后表现。对于每个参数，我们使用逻辑回归模型评估其与死亡率的关联，估算效应大小（比值比，OR，及其95%置信区间，CI），并评估模型的区分度（ROC曲线下面积）、校准度和整体预测准确性。

结果：在2813名早期ARDS患者中，516名（18.3%）符合纳入标准：平均年龄60岁（±16），61%为男性。标准化肺弹性、平台压、驱动压（DP）和4×DP+RR与死亡率显著相关，调整后的比值比（OR）范围从4×DP+RR的1.02（95%CI 1.01-1.03）到标准化肺弹性的1.48（95%CI 1.15-1.95）。与PaO₂/FiO₂和机械功率（MP）相比，这些参数对死亡率的预测准确性更高。机械功率（MP）与死亡率呈现U型关系，但二者之间无显著关联。在校正了呼气末正压（PEEP）和动态气道阻力后，其预测准确性下降，同时PEEP也与死亡率呈现出U型关联。

结论：在ARDS发病第1天测量的标准化肺弹性、驱动压（DP）和4×DP+RR是ICU死亡率的最佳预测因子，其表现优于氧合指标和机械功率（MP）。驱动压（DP）在预测准确性和临床应用的简便性之间达到了最佳平衡。这些结果再次强调了将驱动压（DP）和4×DP+RR作为指导肺保护性通气策略和ARDS严重程度分类的关键指标的重要性。

### 第二部分 AI 大师评价

本研究基于大型国际队列LUNG SAFE的数据，旨在评估急性呼吸窘迫综合征（ARDS）患者中，不同氧合、呼吸力学及通气强度指标对ICU死亡率的预测价值。研究发现，在发病第一天测量的标准化肺弹性、驱动压（DP）及复合指标4×DP+RR是死亡率的强预测因子，其表现优于传统的氧合指数和机械功率。此项研究的价值在于，它在真实世界环境中证实了驱动压等呼吸力学参数在ARDS风险分层中的核心地位，为临床实践中优化肺保护性通气策略、超越传统氧合评估提供了有力证据。

---

## 7. 关于难治性非结核分枝杆菌肺病的管理共识

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198394](https://pubmed.ncbi.nlm.nih.gov/41198394)
**期刊：** The European respiratory journal
**PMID：** 41198394
**DOI：** 10.1183/13993003.00400-2025

### 第一部分 原文与翻译

**英文原标题：** Consensus on Management of Refractory Nontuberculous Mycobacterial Pulmonary Disease.

**英文摘要原文：**
INTRODUCTION: Nontuberculous mycobacteria (NTM) are associated to chronic and challenging infections, particularly pulmonary disease (NTM-PD). While clinical guidelines provide treatment recommendations for the most common disease-causing species, they offer limited guidance on managing treatment failures. This study aims to develop a consensus-based decision-making framework for addressing treatment failure in NTM-PD.

METHODS: A panel of 16 international experts used the e-Delphi method to address gaps in the NTM-PD management. Initial statements derived from an open-ended questionnaire, supported by a prior systematic review. Iterative rounds of expert evaluation were conducted until a consensus was reached on treatment failure definitions, decision-making criteria, therapeutic strategies, and supportive care measures.

RESULTS: Consensus defined treatment failure as the absence of culture conversion after six months of appropriate antimycobacterial therapy, while clinical and radiological deterioration were considered additional but non-mandatory criteria. Treatment intensification or de-escalation decisions were based on patient preferences, clinical status, comorbidities, disease severity, antibiotic tolerance, resistance patterns, and previous treatment history. Treatment intensification highlighted the necessity for personalised multidrug antibiotic regimens. De-escalation strategies focus on delivering optimal, patient-centred supportive care while minimising pharmacological adverse effects, by opting for simplified antibiotic regimens, intermittent antibiotic courses for symptomatic control, or the cessation of antimicrobial therapy.

CONCLUSION: This study offers a structured approach to managing treatment failure in NTM-PD, addressing patient selection, treatment intensification, de-escalation, and supportive care while championing individualised strategies. Future research should concentrate on validating predictive factors for treatment response, refining therapeutic regimens, and investigating host-directed therapies to enhance patient outcomes.

**中文摘要译文：**
引言：非结核分枝杆菌（NTM）与慢性且具有挑战性的感染相关，尤其是肺部疾病（NTM-PD）。尽管临床指南为最常见的致病菌种提供了治疗建议，但其在处理治疗失败方面的指导有限。本研究旨在为处理NTM-PD中的治疗失败问题，制定一个基于共识的决策框架。

方法：一个由16名国际专家组成的小组采用电子德尔菲法，以解决NTM-PD管理中存在的空白。初始陈述来源于一份开放式问卷，并得到前期一项系统性综述的支持。通过多轮迭代的专家评估，直至在治疗失败的定义、决策标准、治疗策略及支持性护理措施上达成共识。

结果：共识将治疗失败定义为经过六个月适当的抗分枝杆菌治疗后，痰菌培养仍未转阴；而临床和影像学上的恶化被视为额外的非强制性标准。治疗强化或降阶梯的决策基于患者偏好、临床状况、合并症、疾病严重程度、抗生素耐受性、耐药模式及既往治疗史。治疗强化强调了个性化多药联合抗生素方案的必要性。降阶梯策略则侧重于提供以患者为中心的最佳支持性护理，同时通过选择简化的抗生素方案、用于症状控制的间歇性抗生素疗程或停止抗菌治疗，来最小化药物不良反应。

结论：本研究为管理NTM-PD中的治疗失败提供了一个结构化的方法，涵盖了患者选择、治疗强化、降阶梯及支持性护理，并倡导个体化策略。未来的研究应集中于验证治疗反应的预测因素、优化治疗方案，并探索宿主导向疗法以改善患者预后。

### 第二部分 AI 大师评价

本研究通过电子德尔菲法汇集了国际专家的共识，旨在为临床实践中极具挑战性的难治性非结核分枝杆菌肺病（NTM-PD）管理提供一个决策框架。其核心贡献在于明确了“治疗失败”的定义，并针对治疗的“强化”与“降阶梯”策略提出了基于多维度因素的决策标准。这项共识填补了现有指南的空白，为临床医生提供了处理复杂病例的结构化路径，强调了个体化与患者为中心的治疗理念，具有重要的临床指导价值。

---

## 8. 白细胞源性ADAM10和ADAM17在细菌性和病毒性肺炎中调节疾病严重程度和全身性结局

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41198388](https://pubmed.ncbi.nlm.nih.gov/41198388)
**期刊：** The European respiratory journal
**PMID：** 41198388
**DOI：** 10.1183/13993003.02060-2024

### 第一部分 原文与翻译

**英文原标题：** Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia.

**英文摘要原文：**
BACKGROUND: Pneumonia caused by viral or bacterial pathogens such as SARS-CoV2 or  may result in life-threatening disease with a strong contribution of proteases' dysregulation. The present study aimed to systematically characterize the contribution of ADAM10 and ADAM17 on leukocytes and circulating exosomes to viral and bacterial pneumonia.

METHODS: The analysis of COVID-19 and bacterial pneumonia patient samples was combined with  experiments in conditional knockout animals lacking either ADAM10 or ADAM17 in leukocytes and cell culture experiments for mechanistic studies.

RESULTS: Hospitalized bacterial pneumonia and COVID-19 patients displayed a severity dependent increase of ADAM10 and ADAM17 activity on exosomes. These exosomes caused pathophysiological changes of cardiomyocytes and the endothelial barrier. In a preclinical murine pneumonia model, we observed that leukocytes contributed to this increase in exosomal proteolytic activity. In the local environment of the lung, ADAM10 orchestrated a pro-inflammatory response with M1 macrophage polarization, increased reactive oxygen species (ROS) generation, cytokine release, tissue damage and oedema formation, whereas ADAM17 seemed to dampen the initial inflammatory response to an anti-infective, ROS-balanced level.

CONCLUSION: Leukocytic ADAM10 and ADAM17 and their release on exosomes may constitute relevant regulatory elements in bacterial and viral pneumonia, with a potential contribution of exosomes to disease progression and systemic inflammatory responses. Therefore, the diagnostic, prognostic, and therapeutic value of ADAM10 and ADAM17 should be evaluated in further preclinical and translational studies, addressing the changes of the immune response and exosomes as cargo vehicles both at local site and for the prevention of systemic effects.

**中文摘要译文：**
背景：由病毒或细菌病原体（如SARS-CoV2等）引起的肺炎可能导致危及生命的疾病，其中蛋白酶的失调起着重要作用。本研究旨在系统地阐明白细胞和循环外泌体上的ADAM10和ADAM17在病毒性和细菌性肺炎中的作用。

方法：本研究结合了对COVID-19和细菌性肺炎患者样本的分析，以及在白细胞中缺乏ADAM10或ADAM17的条件性基因敲除动物中进行的实验，并辅以细胞培养实验进行机理研究。

结果：住院的细菌性肺炎和COVID-19患者表现出外泌体上ADAM10和ADAM17活性的严重程度依赖性增加。这些外泌体引起了心肌细胞和内皮屏障的病理生理学变化。在一个临床前鼠类肺炎模型中，我们观察到白细胞是导致外泌体蛋白水解活性增加的原因。在肺部局部环境中，ADAM10协调了促炎反应，包括M1型巨噬细胞极化、活性氧（ROS）生成增加、细胞因子释放、组织损伤和水肿形成；而ADAM17似乎将初始炎症反应抑制到一种抗感染、ROS平衡的水平。

结论：白细胞源性的ADAM10和ADAM17及其在外泌体上的释放，可能构成了细菌性和病毒性肺炎中的相关调控元件，其中外泌体可能对疾病进展和全身性炎症反应有贡献。因此，应在未来的临床前和转化研究中评估ADAM10和ADAM17的诊断、预后和治疗价值，重点关注免疫反应的变化以及外泌体作为货物载体在局部和预防全身性效应中的作用。

### 第二部分 AI 大师评价

本研究旨在阐明白细胞源性蛋白酶ADAM10和ADAM17在细菌性与病毒性肺炎中的作用。研究结合了临床样本分析与条件性基因敲除动物模型，创新性地揭示了两者在肺部局部免疫反应中扮演着相反的角色：ADAM10促进炎症，而ADAM17则抑制炎症。更重要的是，研究发现这些蛋白酶可通过外泌体释放，介导全身性器官损伤，这为理解肺炎的全身性并发症提供了新视角。这些发现不仅深化了对肺炎病理生理的认识，也为开发新的诊断标志物和治疗靶点提供了重要线索。

---

## 9. 结节病的免疫发病机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41197661](https://pubmed.ncbi.nlm.nih.gov/41197661)
**期刊：** Seminars in respiratory and critical care medicine
**PMID：** 41197661
**DOI：** 10.1055/a-2716-5737

### 第一部分 原文与翻译

**英文原标题：** Immunopathogenesis of Sarcoidosis.

**英文摘要原文：**
Sarcoidosis is a granulomatous disease of unknown cause, triggered by an unidentified antigen. Although classically considered a T cell-mediated disorder with an IFN-γ signature driven by Th1, Th17, and Th17.1 cells, its pathogenesis reflects dysregulated crosstalk between innate and adaptive immunity. Granulomas form through macrophage differentiation at the core, fueled by aberrantly programmed monocytes and sustained by persistent antigen presentation to T cells. Hyperactive macrophages drive excessive peripheral cell recruitment, while dysregulated T cell responses promote T cell expansion, impaired effector regulation, and eventual exhaustion. Deficient regulatory pathways fail to counterbalance this activation, creating a perpetuating inflammatory loop that underlies disease persistence and fibrotic progression. This review integrates up-to-date transcriptomic and biological data to define the cellular and molecular mechanisms that initiate, sustain, and dysregulate immune responses in sarcoidosis.

**中文摘要译文：**
结节病是一种由未明抗原触发的、病因不明的肉芽肿性疾病。尽管传统上认为它是一种由Th1、Th17和Th17.1细胞驱动、具有IFN-γ特征的T细胞介导性疾病，但其发病机制反映了先天性免疫与适应性免疫之间失调的相互作用。肉芽肿的形成以巨噬细胞分化为核心，由异常程序化的单核细胞提供动力，并通过持续的抗原呈递给T细胞而得以维持。过度活跃的巨噬细胞驱动外周细胞的过度招募，而失调的T细胞反应则促进T细胞扩增、效应调节受损，并最终导致T细胞耗竭。有缺陷的调节通路无法平衡这种激活状态，从而形成一个持续的炎症循环，这是疾病持续存在和纤维化进展的基础。这篇综述整合了最新的转录组学和生物学数据，旨在阐明启动、维持和失调结节病免疫反应的细胞及分子机制。

### 第二部分 AI 大师评价

这篇综述文章深入阐述了结节病的免疫发病机制，其核心价值在于整合了最新的转录组学和生物学数据，提出了一个超越传统T细胞中心论的全新视角。文章系统地论述了先天性与适应性免疫失调的相互作用，特别是巨噬细胞、单核细胞与T细胞在肉芽肿形成、炎症持续及纤维化进程中的关键作用。该综述不仅为理解结节病的复杂性提供了清晰的分子与细胞机制框架，也为探索新的治疗靶点（如干预炎症循环）指明了重要方向，对临床和基础研究均有很高的参考价值。

---

## 10. NUDT5通过与PPAT相互作用调控嘌呤代谢及硫唑嘌呤敏感性

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196949](https://pubmed.ncbi.nlm.nih.gov/41196949)
**期刊：** Science (New York, N.Y.)
**PMID：** 41196949
**DOI：** 10.1126/science.adx9717

### 第一部分 原文与翻译

**英文原标题：** NUDT5 regulates purine metabolism and thiopurine sensitivity by interacting with PPAT.

**英文摘要原文：**
Cells generate purine nucleotides through de novo purine biosynthesis (DNPB) and purine salvage. Purine salvage represses DNPB to prevent excessive purine nucleotide synthesis through mechanisms that are incompletely understood. We identified Nudix hydrolase 5 (NUDT5) as a DNPB regulator. During purine salvage, NUDT5 suppresses DNPB independently of its catalytic function but through interaction with phosphoribosyl pyrophosphate amidotransferase (PPAT), the rate-limiting enzyme in the DNPB pathway. The NUDT5-PPAT interaction promoted PPAT oligomerization, suppressed PPAT's enzymatic activity, and facilitated disassembly of the purinosome, a metabolon that functions in DNPB. Disrupting the NUDT5-PPAT interaction overcame DNPB suppression during purine salvage, permitting excessive DNPB and inducing thiopurine resistance. Therefore, NUDT5 governs the balance between DNPB and salvage to maintain appropriate cellular purine nucleotide concentrations.

**中文摘要译文：**
细胞通过从头嘌呤生物合成（DNPB）和嘌呤补救途径生成嘌呤核苷酸。嘌呤补救途径能够抑制DNPB，以防止嘌呤核苷酸的过量合成，但其具体机制尚未完全阐明。我们发现Nudix水解酶5（NUDT5）是DNPB的一个调控因子。在嘌呤补救过程中，NUDT5通过与DNPB途径中的限速酶——磷酸核糖焦磷酸酰胺转移酶（PPAT）相互作用，而非依赖其自身的催化功能来抑制DNPB。NUDT5与PPAT的相互作用促进了PPAT的寡聚化，抑制了其酶活性，并加速了在DNPB中发挥作用的代谢复合体——嘌呤体的解体。破坏NUDT5-PPAT之间的相互作用可以解除在嘌呤补救过程中对DNPB的抑制，从而导致DNPB过度活跃并诱导硫唑嘌呤耐药。因此，NUDT5调控着DNPB与补救途径之间的平衡，以维持细胞内适宜的嘌呤核苷酸浓度。

### 第二部分 AI 大师评价

本研究旨在揭示嘌呤补救途径抑制从头合成（DNPB）的具体分子机制。研究团队发现NUDT5蛋白能够不依赖其酶催化活性，直接与DNPB途径的关键限速酶PPAT相互作用，进而抑制其活性并促进嘌呤体解体。这一关键发现不仅阐明了NUDT5作为连接嘌呤补救与从头合成途径的“开关”分子，调控细胞嘌呤稳态的新功能，也为理解和克服硫唑嘌呤类药物的临床耐药性提供了新的分子靶点和理论依据，具有重要的科研与临床转化价值。

---

## 11. 铁载体头孢菌素HRS-8427注射液在中国健康受试者中的肺内穿透性及药代动力学研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196282](https://pubmed.ncbi.nlm.nih.gov/41196282)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41196282
**DOI：** 10.1128/aac.00702-25

### 第一部分 原文与翻译

**英文原标题：** Intrapulmonary penetration and pharmacokinetics of siderophore cephalosporin HRS-8427 injection in Chinese healthy subjects.

**英文摘要原文：**
HRS-8427, a novel siderophore cephalosporin antibiotic, is under development for treating Gram-negative infections. This study evaluated the intrapulmonary penetration and pharmacokinetic (PK) profile of HRS-8427 injection following single and multiple dose administrations in healthy Chinese subjects. A single-center, randomized, open-label Phase 1 trial enrolled 38 subjects, with 35 completing the study. In the single-dose group, subjects received a 1,500 mg intravenous infusion of HRS-8427 over 2 h. In the multiple-dose group, subjects were administered 2,000 mg of HRS-8427 intravenously every 8 h for four consecutive doses, each infused over 2 h. Bronchoalveolar lavage (BAL) was conducted to collect epithelial lining fluid (ELF) and alveolar macrophage (AM) specimens. PK analysis demonstrated a maximum plasma concentration () of 176 µg/mL and an area under the time-concentration curve from time zero to time infinity (AUC) of 942 h·μg/mL following the single 1,500 mg dose. After multiple 2,000 mg dosing, the  increased to 262 µg/mlL with a corresponding AUC of 1,640 h·μg/mL. The ELF-to-plasma concentration ratio (/) exhibited a time-dependent increase, reaching 12.2% at 8 h post-final dose. Intracellular accumulation in AM remained minimal (<1%). Multiple-dose administration resulted in higher ELF exposure than single dosing. Safety assessments indicated an overall favorable tolerability profile, with most adverse events being mild in severity. Based on PK and microbiological data, a 2,000 mg regimen achieved concentrations exceeding the MIC₉₀ values of major Gram-negative pathogens, supporting further clinical development of HRS-8427 for respiratory and other Gram-negative bacterial infections.CLINICAL TRIALSThis study is registered with Chinese Clinical Trial Registry Platform as ChiCTR2300072350.

**中文摘要译文：**
HRS-8427是一种新型铁载体头孢菌素抗生素，正在开发用于治疗革兰氏阴性菌感染。本研究旨在评估HRS-8427注射液在中国健康受试者中单次及多次给药后的肺内穿透性及药代动力学（PK）特征。这项单中心、随机、开放标签的I期临床试验共招募了38名受试者，其中35名完成了研究。在单次给药组中，受试者接受了1500毫克HRS-8427，经2小时静脉输注。在多次给药组中，受试者每8小时静脉输注2000毫克HRS-8427，每次输注超过2小时，连续给药四次。研究通过支气管肺泡灌洗（BAL）收集了上皮衬液（ELF）和肺泡巨噬细胞（AM）样本。PK分析显示，单次给予1500毫克剂量后，最大血浆浓度（Cmax）为176 µg/mL，从零时到无穷大的时间-浓度曲线下面积（AUC₀-∞）为942 h·μg/mL。多次给予2000毫克剂量后，Cmax增至262 µg/mL，相应的稳态浓度-时间曲线下面积（AUC₀-τ）为1640 h·μg/mL。上皮衬液与血浆的浓度比（CELF/Cplasma）呈现出时间依赖性增加，在末次给药后8小时达到12.2%。其在肺泡巨噬细胞内的蓄积量极低（<1%）。多次给药方案相较于单次给药，能实现更高的上皮衬液药物暴露量。安全性评估显示，该药物总体耐受性良好，大多数不良事件为轻度。基于药代动力学和微生物学数据，2000毫克的给药方案能够达到超过主要革兰氏阴性病原体MIC₉₀值的药物浓度，这支持了HRS-8427在治疗呼吸系统及其他革兰氏阴性菌感染方面的进一步临床开发。临床试验注册：本研究已在中国临床试验注册中心注册，注册号为ChiCTR2300072350。

### 第二部分 AI 大师评价

本研究通过一项I期临床试验，系统评估了新型铁载体头孢菌素HRS-8427在中国健康受试者中的肺内分布和药代动力学特性。研究采用支气管肺泡灌洗等方法，精确测定了药物在血浆、肺上皮衬液及肺泡巨噬细胞中的浓度，发现多次给药能有效提高肺部药物暴露。其关键发现——2000mg剂量下的肺部浓度足以覆盖主要革兰氏阴性菌的MIC₉₀，且安全性良好——为该药物进入后续临床阶段、未来用于治疗呼吸系统感染提供了坚实的科学依据和临床价值。

---

## 12. 东南亚地区成人脓毒症患者转诊前使用抗生素与死亡率的关系：一项前瞻性队列研究的二次分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41196125](https://pubmed.ncbi.nlm.nih.gov/41196125)
**期刊：** Critical care medicine
**PMID：** 41196125
**DOI：** 10.1097/CCM.0000000000006932

### 第一部分 原文与翻译

**英文原标题：** Pre-referral Antibiotics and Mortality Among Adults With Sepsis in Southeast Asia: A Secondary Analysis of a Prospective Cohort Study.

**英文摘要原文：**
OBJECTIVE: Early antibiotics are considered critical for bacterial sepsis treatment, although the benefit of this early timing may differ by the presence of shock. Little evidence exists from low- or middle-income settings. In patients referred from community hospitals to a tertiary center, we tested whether pre-referral antibiotic administration is associated with 28-day survival in sepsis, and whether this association differs by the presence of shock.

DESIGN: Secondary analysis of a prospective cohort study that enrolled patients from 2013 to 2017 with a primary diagnosis of infection made by an attending physician and at least three Surviving Sepsis Campaign criteria for sepsis.

SETTING: Tertiary care hospital in northeastern Thailand.

PATIENTS: A total of 2593 adults with sepsis defined by primary diagnosis of infection and modified Sequential Organ Failure Assessment score greater than or equal to 2 who were referred from community hospitals.

INTERVENTIONS: Antibiotics administered at the referring community hospital.

MEASUREMENTS AND MAIN RESULTS: The median age was 59 years (interquartile range 44-72), 2233 (86.1%) were transferred the same day as initial presentation, and 1897 (73.2%) received antibiotics prior to referral. Blood cultures grew bacteria in 313 (12.1%). Twenty-eight-day mortality was 18.9%. In the propensity score-matched cohort (n = 722 sepsis without shock, n = 244 septic shock), shock modified the association between pre-referral antibiotics and death (interaction p = 0.001). In patients with septic shock, pre-referral antibiotics were associated with lower hazard of death (hazard ratio [HR], 0.38; 95% CI, 0.19-0.75) but in patients without shock there was no association with hazard of death (HR, 1.36; 95% CI, 0.96-1.92).

CONCLUSIONS: In rural Thailand, antibiotic administration prior to referral was associated with lower hazard of death in patients with septic shock. Our findings extend to a resource-limited setting evidence supporting the benefit of early antibiotic administration in septic patients with shock.

**中文摘要译文：**
目的：早期使用抗生素被认为是细菌性脓毒症治疗的关键，尽管这种早期给药的益处可能因是否存在休克而异。来自中低收入环境的证据很少。本研究旨在检验，在从社区医院转诊至三级医疗中心的患者中，转诊前使用抗生素是否与脓毒症患者的28天生存率相关，以及这种关联是否因休克的有无而不同。

设计：本研究是一项前瞻性队列研究的二次分析，该研究在2013年至2017年间入组了由主治医师做出感染初步诊断，并满足至少三项“拯救脓毒症运动”标准的脓毒症患者。

地点：泰国东北部的一家三级监护医院。

患者：共纳入2593名从社区医院转诊的成人脓毒症患者，其脓毒症定义为初步诊断为感染且改良的序贯器官功能衰竭评估（SOFA）评分≥2。

干预措施：在转诊的社区医院给予抗生素治疗。

测量指标与主要结果：患者中位年龄为59岁（四分位距44-72岁），2233名（86.1%）患者在初次就诊当天转院，1897名（73.2%）在转诊前接受了抗生素治疗。血培养细菌阳性者有313名（12.1%）。28天死亡率为18.9%。在倾向性评分匹配队列中（n=722名无休克的脓毒症患者，n=244名脓毒症休克患者），休克状态调节了转诊前抗生素使用与死亡之间的关联（交互作用p = 0.001）。在脓毒症休克患者中，转诊前使用抗生素与更低的死亡风险相关（风险比[HR], 0.38; 95% CI, 0.19-0.75），但在无休克的患者中，其与死亡风险无显著关联（HR, 1.36; 95% CI, 0.96-1.92）。

结论：在泰国农村地区，转诊前使用抗生素与脓毒症休克患者的死亡风险降低相关。我们的研究结果将支持脓毒症休克患者早期使用抗生素获益的证据扩展到了资源有限的环境中。

### 第二部分 AI 大师评价

本研究通过对一项前瞻性队列研究的二次分析，探讨了在泰国农村地区，转诊前使用抗生素对成人脓毒症患者死亡率的影响，并特别关注了休克状态的调节作用。其核心发现是，早期抗生素干预显著降低了脓毒症休克患者的死亡风险，但对无休克患者无此效果。该研究的价值在于，它为资源有限地区提供了重要证据，强调了在脓毒症治疗中根据休克状态进行风险分层和决策的必要性，对优化转诊流程中的早期抗生素策略具有重要的临床指导意义。

---

## 13. 产丁酸肠道菌可预防细菌性肺炎

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40774806](https://pubmed.ncbi.nlm.nih.gov/40774806)
**期刊：** The European respiratory journal
**PMID：** 40774806
**DOI：** 10.1183/13993003.02208-2024

### 第一部分 原文与翻译

**英文原标题：** Butyrate-producing gut bacterium protects against bacterial pneumonia.

**英文摘要原文：**
BACKGROUND: Gut microbiota play a protective role against pneumonia in mice, probably by producing the immunomodulatory short-chain fatty acid butyrate. Yet, butyrate has limited potential for clinical use due to its challenging handling in practice. We performed mouse experiments and translational analyses to determine whether butyrate-producing gut commensals,  and , could provide protection against bacterial pneumonia and serve as next-generation probiotics.

METHODS: We pre-treated C57BL/6J mice with butyrate,  (recently reclassified as ) or , and subsequently infected them intranasally with . To assess the relevance in humans, we assessed associations between rectal levels of , immune responses and clinical outcomes in 115 patients with community-acquired pneumonia (CAP) and in a separate validation cohort.

RESULTS: Pre-treatment with , but not , protected mice against bacterial pneumonia, as reflected by reduced bacterial growth and dissemination, lessened organ damage, and dampened inflammation. Similar to butyrate pre-treatment,  resulted in reduced pulmonary interleukin (IL)-6 and CXCL1. In humans, gut  was decreased during CAP compared to matched controls. CAP patients with higher gut  levels had lower IL-6-producing capacity and downregulated inflammatory gene expression. Higher intestinal  levels were associated with better clinical outcomes in independent cohorts of CAP and critically ill patients, which remained significant when controlled for potential confounders.

CONCLUSION: This is the first study showing that the gut commensal  provides protection against bacterial pneumonia and has translational potential. This motivates future studies investigating the clinical potential of  as a novel probiotic for pneumonia.

**中文摘要译文：**
背景：肠道菌群可能通过产生免疫调节性短链脂肪酸丁酸，在小鼠肺炎中发挥保护作用。然而，由于丁酸在实践中难以处理，其临床应用潜力有限。我们进行了小鼠实验和转化分析，旨在确定产丁酸的肠道共生菌——普拉梭菌（Faecalibacterium prausnitzii）和直肠真杆菌（Eubacterium rectale）——是否能预防细菌性肺炎并作为下一代益生菌。

方法：我们用丁酸、普拉梭菌（近期被重新分类为 Faecalicatena prausnitzii）或直肠真杆菌对C57BL/6J小鼠进行预处理，随后经鼻内感染肺炎链球菌（Streptococcus pneumoniae）。为评估其在人类中的相关性，我们在115名社区获得性肺炎（CAP）患者和一个独立的验证队列中，评估了直肠普拉梭菌水平、免疫反应和临床结局之间的关联。

结果：普拉梭菌（而非直肠真杆菌）的预处理可保护小鼠免受细菌性肺炎的侵害，表现为细菌生长和播散减少、器官损伤减轻以及炎症反应减弱。与丁酸预处理相似，普拉梭菌预处理导致肺部白细胞介素（IL）-6和CXCL1水平降低。在人类中，与匹配的对照组相比，CAP患者肠道内的普拉梭菌水平有所下降。肠道普拉梭菌水平较高的CAP患者，其IL-6产生能力较低，且炎症基因表达下调。在独立的CAP和危重症患者队列中，较高的肠道普拉梭菌水平与更好的临床结局相关，在校正潜在混杂因素后，这种关联仍然显著。

结论：这是首个证明肠道共生菌普拉梭菌能预防细菌性肺炎并具有转化潜力的研究。这激励了未来开展研究，以探索普拉梭菌作为一种新型肺炎益生菌的临床潜力。

### 第二部分 AI 大师评价

该研究旨在探究产丁酸的关键肠道共生菌`Faecalibacterium prausnitzii`是否能预防细菌性肺炎，并评估其作为下一代益生菌的潜力。研究巧妙地结合了小鼠动物模型与人体临床队列的转化医学分析，发现`F. prausnitzii`不仅能在动物实验中有效减轻肺炎的严重程度，其在社区获得性肺炎患者体内的丰度也与更弱的炎症反应和更优的临床结局显著相关。本研究的创新价值在于，它首次从特定菌株层面证实了肠道细菌对肺部感染的直接保护作用，为“肠—肺轴”理论提供了坚实证据，并为开发靶向益生菌来防治肺炎这一重大临床挑战开辟了极具前景的新路径。

---

## 14. 嗜碱性粒细胞在急性呼吸窘迫综合征消退过程中的新兴作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40744690](https://pubmed.ncbi.nlm.nih.gov/40744690)
**期刊：** The European respiratory journal
**PMID：** 40744690
**DOI：** 10.1183/13993003.01150-2024

### 第一部分 原文与翻译

**英文原标题：** Emerging roles of basophils in the resolution of acute respiratory distress syndrome.

**英文摘要原文：**
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a severe form of lung failure with a high mortality rate and no effective pharmacological therapy. Although the cellular and molecular mechanisms involved in ARDS onset have been extensively studied, those governing its resolution remain unclear. Recent human cohort studies have suggested an association between ARDS severity and low blood basophil count. Therefore, in this study, we investigated the roles of basophils in ARDS pathogenesis and resolution.

METHODS: We examined the effects of basophil depletion in lipopolysaccharide-induced ARDS model mice and assessed the roles of basophils in ARDS onset and resolution using genetically engineered mice and single-cell RNA-sequencing analysis.

RESULTS: Intratracheal administration of lipopolysaccharides induced severe lung inflammation, characterised by extensive neutrophil infiltration, followed by gradual recovery to homeostatic conditions. Basophil depletion impaired the resolution but not the induction of lung inflammation, highlighting the critical role of basophils in the resolution phase of ARDS. Basophils accumulated in the lungs were the primary sources of the cytokine interleukin (IL)-4. Mice with basophil-specific IL-4 deficiency failed to resolve lung inflammation, as did mice with neutrophil-specific IL-4 receptor deficiency. Transcriptomic analysis revealed that basophil-derived IL-4 acted on neutrophils to suppress the anti-apoptotic gene and pro-inflammatory mediator expression.

CONCLUSIONS: Overall, our findings revealed that basophils played essential roles in the ARDS resolution phase, primarily by producing IL-4, which acted on neutrophils to alleviate lung inflammation in ARDS model mice.

**中文摘要译文：**
背景：急性呼吸窘迫综合征（ARDS）是一种严重的肺功能衰竭，死亡率高，且缺乏有效的药物治疗。尽管与ARDS发病相关的细胞和分子机制已得到广泛研究，但主导其消退的机制仍不清楚。近期的人群队列研究表明，ARDS的严重程度与血液中嗜碱性粒细胞计数偏低有关。因此，本研究旨在探究嗜碱性粒细胞在ARDS发病机制和消退过程中的作用。

方法：我们检验了在脂多糖诱导的ARDS模型小鼠中清除嗜碱性粒细胞所产生的影响，并利用基因工程小鼠和单细胞RNA测序分析评估了嗜碱性粒细胞在ARDS发病和消退中的作用。

结果：气管内施用脂多糖诱发了以大量中性粒细胞浸润为特征的严重肺部炎症，随后逐渐恢复至稳态。清除嗜碱性粒细胞损害了肺部炎症的消退过程，但并未影响其诱发过程，这凸显了嗜碱性粒细胞在ARDS消退阶段的关键作用。积聚在肺部的嗜碱性粒细胞是细胞因子白细胞介素-4（IL-4）的主要来源。嗜碱性粒细胞特异性IL-4缺陷的小鼠未能消退肺部炎症，同样地，中性粒细胞特异性IL-4受体缺陷的小鼠也未能消退炎症。转录组学分析显示，源自嗜碱性粒细胞的IL-4作用于中性粒细胞，抑制其抗凋亡基因和促炎介质的表达。

结论：总的来说，我们的研究结果揭示，嗜碱性粒细胞在ARDS的消退阶段发挥了至关重要的作用，这主要是通过产生IL-4，后者作用于中性粒细胞，从而在ARDS模型小鼠中缓解肺部炎症。

### 第二部分 AI 大师评价

本研究旨在揭示嗜碱性粒细胞在急性呼吸窘迫综合征（ARDS）病程中的作用。研究团队通过构建小鼠模型并结合基因工程与单细胞测序等前沿技术，发现嗜碱性粒细胞并非参与炎症的起始，而是在炎症的“消退期”扮演着关键角色。其核心发现是，肺内聚集的嗜碱性粒细胞通过分泌IL-4作用于中性粒细胞，从而抑制炎症并促进组织修复。这项研究的创新之处在于阐明了嗜碱性粒细胞在ARDS恢复过程中的保护性功能及其分子机制，为开发促进ARDS消退的靶向治疗策略提供了新的科学依据和潜在靶点。

---

## 15. 调控浸润性CD206+巨噬细胞可抑制肺淋巴管肌瘤病的进展。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40639874](https://pubmed.ncbi.nlm.nih.gov/40639874)
**期刊：** The European respiratory journal
**PMID：** 40639874
**DOI：** 10.1183/13993003.00084-2025

### 第一部分 原文与翻译

**英文原标题：** Modulation of infiltrating CD206 macrophages restricts progression of pulmonary lymphangioleiomyomatosis.

**英文摘要原文：**
RATIONALE: Lymphangioleiomyomatosis (LAM) is a low-grade neoplasm caused by the proliferation of tuberous sclerosis complex (TSC) 1- or TSC2-deficient LAM cells, resulting in progressive cystic lung disease. The currently approved treatment for LAM delays disease progression but the disease recurs if treatment is discontinued. Therefore, new therapeutic targets and/or strategies are necessary for a cure. Immunosuppressive M2-like macrophages are involved in the progression of various cancers, but their role in the pathophysiology of LAM and as a putative therapeutic target is unknown.

METHODS: To identify the different immune cell populations involved in LAM, we generated a single-cell transcriptomic map of pulmonary LAM. Interactions between macrophages and LAM cells were studied using the Visium spatial transcriptomic platform and immunofluorescence staining on human pulmonary LAM specimens. Direct co-culture models were used to characterise the influence of TSC2-deficient cells on macrophage differentiation. The efficacy of targeting M2-like macrophages was assessed in preclinical mouse models of TSC2-deficient subcutaneous tumours treated with RP-182, a synthetic peptide which reprogrammes macrophages towards an antitumour M1-like phenotype.

RESULTS: Single-cell RNA-sequencing analysis revealed that the majority of macrophages in pulmonary LAM display immunosuppressive markers, including  and . Spatial transcriptomic and immunofluorescence analyses showed that M2 macrophages are in close proximity to LAM cells and that LAM cells that are in close proximity to macrophages highly express macrophage-homing factor chemokine ligand . , co-culture of human and mouse macrophages with TSC2-deficient cells resulted in the upregulation of M2-marker-expressing macrophages. Targeting M2 macrophages  treatment with the CD206 modulator RP-182 impaired the growth of TSC2-deficient tumours .

CONCLUSION: LAM cells recruit and polarise macrophages towards an M2 phenotype. M2-like CD206 macrophages may represent a potential therapeutic target in LAM.

**中文摘要译文：**
背景：淋巴管肌瘤病（LAM）是一种由结节性硬化复合物（TSC）1或TSC2缺陷的LAM细胞增殖引起的低度恶性肿瘤，导致进行性囊性肺部疾病。目前已批准的LAM疗法可延缓疾病进展，但若停止治疗，疾病会复发。因此，为实现治愈，开发新的治疗靶点和/或策略势在必行。免疫抑制性的M2样巨噬细胞参与多种癌症的进展，但其在LAM病理生理中的作用以及作为潜在治疗靶点的价值尚不明确。

方法：为了鉴定参与LAM的不同免疫细胞群，我们构建了肺部LAM的单细胞转录组图谱。我们利用Visium空间转录组学平台和免疫荧光染色技术研究了人肺LAM标本中巨噬细胞与LAM细胞间的相互作用。通过直接共培养模型，我们探究了TSC2缺陷细胞对巨噬细胞分化的影响。在TSC2缺陷的皮下肿瘤临床前小鼠模型中，我们使用合成肽RP-182（一种能将巨噬细胞重编程为抗肿瘤M1样表型的药物）治疗，以评估靶向M2样巨噬细胞的疗效。

结果：单细胞RNA测序分析显示，肺部LAM中的大多数巨噬细胞表达免疫抑制性标志物，包括MARCO和CD163。空间转录组学和免疫荧光分析表明，M2巨噬细胞与LAM细胞紧密相邻，且邻近巨噬细胞的LAM细胞高表达巨噬细胞归巢因子趋化因子配体CCL2。体外实验中，将人和小鼠的巨噬细胞与TSC2缺陷细胞共培养，导致表达M2标志物的巨噬细胞上调。体内实验中，使用CD206调节剂RP-182靶向M2巨噬细胞的治疗抑制了TSC2缺陷肿瘤的生长。

结论：LAM细胞能够招募巨噬细胞并将其极化为M2表型。M2样CD206+巨噬细胞可能代表了LAM的一个潜在治疗靶点。

### 第二部分 AI 大师评价

本研究精准地揭示了肺淋巴管肌瘤病（LAM）中肿瘤微环境的关键免疫调控机制。研究团队综合运用单细胞与空间转录组学等前沿技术，证实了LAM细胞能主动招募并诱导巨噬细胞向促进肿瘤生长的M2表型极化。更具突破性的是，研究发现通过靶向调节CD206+巨噬细胞（使用合成肽RP-182）可有效抑制肿瘤进展，这为LAM治疗开辟了超越传统mTOR抑制剂的免疫调节新路径，具有重要的临床转化潜力。

---

## 16. 特发性肺纤维化患者预测性6分钟步行评分的开发与验证

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40610052](https://pubmed.ncbi.nlm.nih.gov/40610052)
**期刊：** The European respiratory journal
**PMID：** 40610052
**DOI：** 10.1183/13993003.02565-2024

### 第一部分 原文与翻译

**英文原标题：** Development and validation of a predictive 6-min walk score in patients with idiopathic pulmonary fibrosis.

**英文摘要原文：**
BACKGROUND: The 6-min walk test (6MWT) provides an assessment of patient function and has been employed in interstitial lung disease clinical trials as an end-point. The ISABELA studies were two replicate randomised controlled trials of idiopathic pulmonary fibrosis (IPF) that included a regimented 6MWT protocol. The goal of this study was to combine 6MWT components into a pragmatic, easy to apply, composite clinical prediction score.

METHODS: 6MWT parameters associated with time to death or respiratory hospitalisation in the ISABELA studies were integrated into a single composite score. This score was then validated in an external cohort.

RESULTS: There were 1251 patients in the derivation set with 83 respiratory-related hospitalisations and 21 deaths observed after 48 weeks. After multivariable analysis, four parameters were independently predictive of outcomes: Borg dyspnoea score, oxygen flow rate, oxygen saturation nadir and the 6-min walk distance. A pragmatic model, termed the ODDS (oxygen, distance, dyspnoea, saturation) was then developed. This performed better than the individual parameters alone with an area under the curve (AUC) of 0.797, 0.781 and 0.766 for events at 12, 24 and 48 weeks, respectively. The ODDS model was similarly accurate when applied to the external validation set (n=295) at 48 weeks (AUC 0.758, 95% CI 0.688-0.825).

CONCLUSION: The 6MWT imparts important prognostic information which is best captured by combining constituent variables in a composite score system. The ODDS model might find utility in the clinical setting as well as in IPF studies where it can be used to risk-stratify patients for outcomes.

**中文摘要译文：**
背景：6分钟步行试验（6MWT）可用于评估患者的功能，并已被用作间质性肺疾病临床试验的终点。ISABELA研究是两项针对特发性肺纤维化（IPF）的重复性随机对照试验，其中包含了标准化的6MWT方案。本研究旨在将6MWT的各项组成部分整合成一个实用、易于应用的复合临床预测评分。

方法：在ISABELA研究中，与死亡或呼吸系统相关住院时间相关的6MWT参数被整合到一个单一的复合评分中。随后，该评分在一个外部队列中得到了验证。

结果：在推导队列中，共有1251名患者，在48周后观察到83例呼吸系统相关住院和21例死亡。经多变量分析，四个参数可独立预测结局：Borg呼吸困难评分、氧流量、最低血氧饱和度和6分钟步行距离。随后，研究人员开发了一个实用模型，命名为ODDS（氧气、距离、呼吸困难、饱和度）。该模型的表现优于任何单一参数，其在12、24和48周时预测事件的曲线下面积（AUC）分别为0.797、0.781和0.766。当应用于外部验证队列（n=295）时，ODDS模型在48周时的准确性也同样很高（AUC 0.758, 95% CI 0.688-0.825）。

结论：6MWT提供了重要的预后信息，通过将各组成变量整合到一个复合评分系统中可以最好地捕捉这些信息。ODDS模型可能在临床实践以及IPF研究中具有应用价值，可用于对患者进行结局风险分层。

### 第二部分 AI 大师评价

本研究旨在针对特发性肺纤维化（IPF）患者，开发并验证一种基于6分钟步行试验（6MWT）的复合预测评分。研究者利用大型临床试验数据，通过多变量分析筛选出四个关键预测指标（氧流量、步行距离、呼吸困难评分、最低血氧饱和度），并将其整合成一个名为“ODDS”的实用模型。该研究的关键创新在于，它证明了整合多个6MWT参数的复合评分比任何单一参数（如步行距离）更能准确预测患者的死亡或呼吸系统住院风险，且其有效性在外部队列中得到验证。这个ODDS模型简单易用，为临床医生提供了更精准的风险分层工具，并可能成为未来IPF研究中一个有价值的评估终点。

---

速递结束，祝您工作愉快！